Is Shelter Pharma overvalued or undervalued?
As of May 30, 2025, Shelter Pharma is rated "very attractive" due to its undervalued status with a PE ratio of 6.39, an EV to EBITDA of 4.15, and a PEG ratio of 0.40, significantly lower than peers like Sun Pharmaceutical and Cipla, while also outperforming the Sensex with recent returns of 4.77% and 17.45%.
As of 30 May 2025, Shelter Pharma has moved from a grade of "does not qualify" to "very attractive," indicating a significant improvement in its valuation outlook. The company is currently considered undervalued based on its strong financial ratios, including a PE ratio of 6.39, an EV to EBITDA of 4.15, and a PEG ratio of 0.40. These figures suggest that Shelter Pharma is trading at a discount compared to its earnings growth potential.In comparison to its peers, Shelter Pharma's valuation metrics stand out. For instance, Sun Pharmaceutical Industries Ltd. has a PE ratio of 35.25, while Cipla Ltd. has a PE ratio of 22.99, both indicating that Shelter Pharma is significantly cheaper relative to these competitors. Additionally, the company's recent stock performance has outpaced the Sensex over the past week and month, with returns of 4.77% and 17.45%, respectively, reinforcing the attractiveness of its current valuation.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Most Read
